MYND Life Sciences IncCanadian Securities Exchange:MYNDView on OTCQB
- LAST PRICE0.0750
- TODAY'S CHANGE (%)0.0250 (50.0000%)
- Bid / Lots0.0600/ 100
- Ask / Lots0.0750/ 1
- Open / Previous Close0.0550 / 0.0500
- Day Range
- 52 Week Range
- Volume9,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYND |
|---|---|---|
| 10:15 ET | 4000 | 0.055 |
| 11:59 ET | 5000 | 0.075 |
Nov 12, 2024
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business, from 8:06PM ET on Tuesday Nov 12, 2024 by Dow Jones
8:06PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MYND Life Sciences Inc | 1.8M | -6.3x | --- |
PsyBio Therapeutics Corp | 1.3M | -0.3x | --- |
Algernon Pharmaceuticals Inc | 2.0M | -0.4x | --- |
Restart Life Sciences Corp | 1.5M | -1.9x | --- |
Claritas Pharmaceuticals Inc | 977.8K | -0.3x | --- |
Vaxil Bio Ltd | 1.4M | -12.5x | --- |
Company Information
MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin and/or its analogs. It is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions as well as multiple sclerosis, and Alzheimer’s disease. Its programs include MYND-604 and MYND-778.
Contact Information
- Headquarters
- 105-2248 Elgin AvePORT COQUITLAM, BC, Canada V3C 2B2
- Phone
- 780-965-0122
- Fax
- ---
Executives
- Executive Chairman of the Board
- Lyle Oberg
- President, Chief Executive Officer
- John Campbell
- Chief Financial Officer
- Paul Ciullo
- Chief Operating Officer
- Jordan Cleland
- Chief Scientific Officer, Director
- Wilfred Jeffries
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 24.4M |
MYND Life Sciences Inc does not pay a dividend. | |
Beta | 1.21 |
EPS | $-0.01 |
Book Value | $-0.10 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
